Brief: TYK Medicines Inc Announces Inclusion Of Asandeutertinib In List Of Products For Priority Review By Center For Drug Evaluation Of NMPA China
29/01/2026 10:37
Jan 29 (Reuters) - TYK Medicines Inc 2410.HK: INCLUSION OF ASANDEUTERTINIB IN LIST OF PRODUCTS FOR PRIORITY REVIEW BY CENTER FOR DRUG EVALUATION OF NMPA CHINA Further company coverage: 2410.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on TYK Medicines
See all newsBrief: TYK Medicines Says Chairman Buys 635,000 H Shares Between Sept 8 And Sept 10, 2026
Brief: Tyk Medicines Says Chairman Purchases Co's Shares On Open Market
Brief: TYK Medicines Says Asandeutertinib Mesylate Tablets (TY-9591) Obtains Conditional Marketing Approval From NMPA
Brief: TYK Medicines Files Legal Proceedings Against Sichuan Huiyu Pharmaceutical Over TY-9591 Agreements
Brief: Tyk Medicines Enters License And Collaboration Agreement With Qilu For Ty-9591 In China